Synergistic Effects of Bortezomib-OV Therapy and Anti-Invasive Strategies in Glioblastoma: A Mathematical Model

被引:11
|
作者
Kim, Yangjin [1 ]
Lee, Junho [1 ]
Lee, Donggu [1 ]
Othmer, Hans G. [2 ]
机构
[1] Konkuk Univ, Dept Math, Seoul 05029, South Korea
[2] Univ Minnesota, Sch Math, Minneapolis, MN 55455 USA
来源
CANCERS | 2019年 / 11卷 / 02期
关键词
glioblastoma; oncolytic virus; mathematical model; bortezomib; ER stress; apoptosis; CSPG; NF-KAPPA-B; VESICULAR STOMATITIS-VIRUS; PROTEASOME INHIBITOR PS-341; NEWCASTLE-DISEASE VIRUS; CHONDROITIN SULFATE PROTEOGLYCANS; MULTIPLE-MYELOMA CELLS; LONG-TERM SURVIVAL; GENE-THERAPY; HYBRID MODEL; IN-VITRO;
D O I
10.3390/cancers11020215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is well-known that the tumor microenvironment (TME) plays an important role in the regulation of tumor growth and the efficacy of anti-tumor therapies. Recent studies have demonstrated the potential of combination therapies, using oncolytic viruses (OVs) in conjunction with proteosome inhibitors for the treatment of glioblastoma, but the role of the TME in such therapies has not been studied. In this paper, we develop a mathematical model for combination therapies based on the proteosome inhibitor bortezomib and the oncolytic herpes simplex virus (oHSV), with the goal of understanding their roles in bortezomib-induced endoplasmic reticulum (ER) stress, and how the balance between apoptosis and necroptosis is affected by the treatment protocol. We show that the TME plays a significant role in anti-tumor efficacy in OV combination therapy, and illustrate the effect of different spatial patterns of OV injection. The results illustrate a possible phenotypic switch within tumor populations in a given microenvironment, and suggest new anti-invasion therapies.
引用
收藏
页数:29
相关论文
共 22 条
  • [21] Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy: For suppression of lymph node and distant metastasis in a murine melanoma model
    Sasaki, Yuki
    Maeda, Taku
    Hojo, Masahiro
    Miura, Takahiro
    Ishikawa, Kosuke
    Funayama, Emi
    Okada, Kazufumi
    Yamamoto, Yuhei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 740
  • [22] Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1
    Gaweco, Anderson
    Thell, Kathrin
    Urban, Maria
    Harrauer, Julia
    Haslinger, Isabella
    Dohnal, Alexander
    Lametschwandtner, Guenther
    Drobits, Karin
    Gugenberger, Romana
    Muehleisen, Hannes
    Penninger, Josef
    Becerra, Carlos
    Chung, Vincent
    El-Khoueiry, Anthony
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)